De-escalation of nodal surgery in clinically node-positive breast cancer

Basit Öğe Kaydı
dc.contributor.authorCabioğlu, Neslihan
dc.contributor.authorKoçer, Havva Belma
dc.contributor.authorKaranlık, Hasan
dc.contributor.authorGülçelik, Mehmet Ali
dc.contributor.authorİğci, Abdullah
dc.contributor.authorMüslümanoğlu, Mahmut
dc.contributor.authorUras, Cihan
dc.contributor.authorMantoğlu, Barış
dc.contributor.authorTrabulus, Didem Can
dc.contributor.authorAkgül, Giray
dc.contributor.authorTükenmez, Mustafa
dc.contributor.authorŞenol, Kazım
dc.contributor.authorÖzkurt, Enver
dc.contributor.authorŞen, Ebru
dc.contributor.authorKaradeniz Çakmak, Güldeniz
dc.contributor.authorBademler, Süleyman
dc.contributor.authorEmiroğlu, Selman
dc.contributor.authorYıldırım, Nilüfer
dc.contributor.authorKara, Halil
dc.contributor.authorDağ, Ahmet
dc.contributor.authorDilege, Ece
dc.contributor.authorAltınok, Ayşe
dc.contributor.authorBaşaran, Gül
dc.contributor.authorVarol, Ecenur
dc.contributor.authorUğurlu, Ümit
dc.contributor.authorBölükbaşı, Yasemin
dc.contributor.authorErsoy, Yeliz Emine
dc.contributor.authorZengel, Baha
dc.contributor.authorKaraman, Niyazi
dc.contributor.authorÖzbaş, Serdar
dc.contributor.authorZer, Leyla
dc.contributor.authorKılıç, Halime Gül
dc.contributor.authorAğcaoğlu, Orhan
dc.contributor.authorSakman, Gürhan
dc.contributor.authorUtkan, Zafer
dc.contributor.authorSoyder, Aykut
dc.contributor.authorAkcan, Alper
dc.contributor.authorErgün, Sefa
dc.contributor.authorYılmaz, Ravza
dc.contributor.authorAydıner, Adnan
dc.contributor.authorSoran, Atilla
dc.contributor.authorİbiş, Kamuran
dc.contributor.authorÖzmen, Vahit
dc.date.accessioned2025-01-07T11:51:38Z
dc.date.available2025-01-07T11:51:38Z
dc.date.issued2025en_US
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü,Genel Cerrahi Ana Bilim Dalıen_US
dc.description.abstractImportance: Increasing evidence supports the oncologic safety of de-escalating axillary surgery for patients with breast cancer after neoadjuvant chemotherapy (NAC). Objective: To evaluate the oncologic outcomes of de-escalating axillary surgery among patients with clinically node (cN)-positive breast cancer and patients whose disease became cN negative after NAC (ycN negative). Design, setting, and participants: In the NEOSENTITURK MF-1803 prospective cohort registry trial, patients from 37 centers with cT1-4N1-3M0 disease treated with sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) alone or with ypN-negative or ypN-positive disease after NAC were recruited between February 15, 2019, and January 1, 2023, and evaluated. Exposure: Treatment with SLNB or TAD after NAC. Main outcomes and measures: The primary aim of the study was axillary, locoregional, or distant recurrence rates; disease-free survival; and disease-specific survival. Number of axillary lymph nodes removed was also evaluated. Results: A total of 976 patients (median age, 46 years [range, 21-80 years]) with cT1-4N1-3M0 disease underwent SLNB (n = 620) or TAD alone (n = 356). Most of the cohort had a mapping procedure with blue dye alone (645 [66.1%]) with (n = 177) or without (n = 468) TAD. Overall, no difference was found between patients treated with TAD and patients treated with SLNB in the median number of total lymph nodes removed (TAD, 4 [3-6] vs SLNB, 4 [3-6]; P = .09). Among patients with ypN-positive disease, those who underwent TAD were more likely to have a lower median lymph node ratio (TAD, 0.28 [IQR, 0.20-0.40] vs SLNB, 0.33 [IQR, 0.20-0.50]; P = .03). At a median follow-up of 39 months (IQR, 29-48 months), no significant difference was found in the rates of ipsilateral axillary recurrence (0.3% [1 of 356] vs 0.3% [2 of 620]; P ≥ .99) or locoregional recurrence (0.6% [2 of 356] vs 1.1% [7 of 620]; P = .50) between the TAD and SLNB groups, with an overall locoregional recurrence rate of 0.9% (9 of 976). The initial clinical tumor stage, pathologic complete response, and use of blue dye alone as a mapping procedure were not associated with the outcome. Even though patients with TAD demonstrated an increased disease-free survival rate compared with the SLNB group, this difference did not reach statistical significance (94.9% vs 92.6%; P = .07). Factors associated with decreased 5-year disease-specific survival were cN2-3 axillary stage (cN1, 98.7% vs cN2-3, 96.8%; P = .03) and nonluminal type tumor pathologic characteristics (luminal, 98.9% vs nonluminal, 96.9%; P = .007). Conclusions and relevance: The short-term results suggest very low rates of axillary and locoregional recurrence in a select group of patients with cN-negative disease after NAC treated with TAD alone or SLNB alone followed by regional nodal irradiation regardless of the SLNB technique or nodal pathology. Whether TAD might provide a clear survival advantage compared with SLNB remains to be proven in studies with longer follow-up.en_US
dc.identifier.citationCabioglu, N., Koçer, H.B., Karanlik, H., Gülçelik, M.A., Igci, A., Müslümanoglu, M., Uras, C., Mantoglu, B., Trabulus, D.C., Akgül, G., Tükenmez, M., Senol, K., Özkurt, E., Sen, E., Karadeniz Çakmak, G., Bademler, S., Emiroglu, S., Yildirim, N., Kara, H., Dag, A., Dilege, E., Altinok, A., Basaran, G., Varol, E., Ugurlu, Ü., Bölükbasi, Y., Ersoy, Y.E., Zengel, B., Karaman, N., Özbas, S., Zer, L., Gül Kiliç, H., Agcaoglu, O., Sakman, G., Utkan, Z., Soyder, A., Akcan, A., Ergün, S., Yilmaz, R., Aydiner, A., Soran, A., Ibis, K., Özmen, V. (2025). De-escalation of nodal surgery in clinically node-positive breast cancer. JAMA Surgery. 10.1001/jamasurg.2024.5913.en_US
dc.identifier.issn2168-6254
dc.identifier.issn2168-6262
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5138
dc.identifier.wosWOS:001389480800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorAltınok, Ayşe
dc.language.isoen
dc.relation.ispartofJAMA Surgery
dc.relation.isversionof10.1001/jamasurg.2024.5913en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNodal surgeryen_US
dc.subjectBreast canceren_US
dc.subjectNEOSENTITURKen_US
dc.titleDe-escalation of nodal surgery in clinically node-positive breast cancer
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu